Zoetis Inc (NYSE:ZTS) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 4,300,000 shares, a growth of 8.1% from the May 15th total of 3,977,000 shares. Based on an average daily trading volume, of 2,040,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.9% of the company’s stock are short sold.
In other Zoetis news, CFO Glenn David sold 8,191 shares of the business’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $102.22, for a total value of $837,284.02. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Willie M. Reed sold 1,900 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $110.58, for a total transaction of $210,102.00. Following the completion of the sale, the director now directly owns 2,816 shares in the company, valued at approximately $311,393.28. The disclosure for this sale can be found here. Insiders have sold 76,613 shares of company stock valued at $7,963,366 over the last quarter. Corporate insiders own 0.29% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in Zoetis during the 1st quarter valued at about $25,000. Glassman Wealth Services increased its stake in Zoetis by 306.5% during the 1st quarter. Glassman Wealth Services now owns 252 shares of the company’s stock valued at $25,000 after purchasing an additional 190 shares in the last quarter. Berman Capital Advisors LLC bought a new stake in Zoetis during the 4th quarter valued at about $26,000. Private Ocean LLC bought a new stake in Zoetis during the 1st quarter valued at about $27,000. Finally, Resources Investment Advisors Inc. bought a new stake in Zoetis during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 90.18% of the company’s stock.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.09. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.45 billion. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. Zoetis’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period last year, the business earned $0.75 EPS. As a group, equities research analysts anticipate that Zoetis will post 3.48 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be paid a dividend of $0.164 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a yield of 0.57%. Zoetis’s dividend payout ratio is currently 21.09%.
ZTS has been the topic of a number of analyst reports. BMO Capital Markets upped their target price on shares of goeasy from C$55.00 to C$60.00 in a report on Thursday, May 9th. Zacks Investment Research lowered shares of GALP ENERGIA SG/ADR from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Barclays reissued a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Finally, Bank of America set a $221.00 price objective on shares of Constellation Brands and gave the stock a “buy” rating in a report on Monday, July 1st. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $110.40.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.